Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA investigates CT scan radiation overexposure risk

This article was originally published in The Gray Sheet

Executive Summary

FDA is conducting a safety investigation of CT brain perfusion scans performed at a single facility after learning of radiation overexposures at that location. Over an 18-month period, 206 patients at the facility received radiation doses at approximately eight times the appropriate level, in some cases resulting in hair loss and erythema, FDA says. While the event involved just one facility, "this situation may reflect more widespread problems with CT quality assurance programs and may not be isolated to this particular facility or this imaging procedure," the agency writes in an Oct. 8 initial safety notification. Hospitals and CT facilities should review CT protocols and carefully monitor radiation dose indices before and after scans, FDA says

You may also be interested in...

FDA Investigates CT Radiation Overdose In Multiple States, Facilities

FDA is investigating hundreds of cases of radiation overexposure from computed tomography (CT) imaging scans to determine whether the overdoses were caused by human error or a problem with the devices

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts